Skip to main content

Personalised interception of autoimmune diseases: Immunopathogenesis, trials and implementation

GoToWebinar

 

This webinar from our Regional & Affinity Group series is brought to you by the BSI West of Scotland Immunology Group. This session will be presented by Professor Ranjeny Thomas and will take place on Tuesday 27 October, 11:00 to 11:45 BST. 

Autoimmune diseases, including rheumatoid arthritis and type 1 diabetes, develop and persist due to the failure of immune self-tolerance. Patients rarely achieve drug-free remission after diagnosis, and although at-risk individuals can be identified, disease cannot yet be successfully intercepted. Precision medicine is increasingly offering solutions to diseases that have been incurable. This talk examines progress in the field of antigen-specific immunotherapy for interception and control of autoimmune disease.


Speaker: Professor Ranjeny Thomas, Professor of Rheumatology, University of Queensland

Professor Thomas is Professor of Rheumatology at University of Queensland, Translational Research Institute, consultant rheumatologist at Princess Alexandra Hospital, fellow of the Australian Academy of Health and Medical Sciences and Chief Technical Officer of the Uniquest spin-off company Dendright. In the recent Queen’s Birthday Honours, she was awarded member of the Order of Australia.

Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed dendritic cell-based antigen-specific immunotherapy in the first proof-of-concept trial in Rheumatoid Arthritis. She developed a liposome immunotherapy that targets dendritic cells to induce antigen-specific tolerance. The product, DEN181, was developed by Dendright, in partnership with Janssen-Biotech, the US pharmaceutical subsidiary of Johnson and Johnson, and tested in a phase 1b clinical trial in RA. Her team recently partnered with CSL to develop immunotherapy for Sjogren’s syndrome. Thomas is progressing the development of liposome-based tolerance strategies in autoimmune diseases, as well as nanoparticle-based dendritic cell targeted cancer vaccines. She has contributed major insights into how the microbiome is involved in causing spondyloarthropathy, leading to the development of disease biomarkers and therapeutic strategies.


This webinar is free for all BSI members. Non-members will be charged £10. You can join the BSI online - membership provides many benefits to help you progress your career. Undergraduate membership is free.


Miltenyi